China is a large country with liver cancer, accounting for 55% of global incidence and 45% of global deaths. Qin Shukui, director of the National Army Oncology Center and director of the National Institute for Drug Clinical Trials, pointed out that many western developed countries have established liver cancer diagnosis and treatment centers, i.e. multidisciplinary collaborative team diagnosis and treatment model to carry out standardized and comprehensive diagnosis and treatment, but it is difficult to build a multidisciplinary joint diagnosis and treatment mechanism for liver cancer in China due to the lack of a unified diagnosis and treatment plan. The release of “Expert Consensus on Standardized Diagnosis and Treatment of Primary Liver Cancer” will promote the establishment of this mechanism in China, reduce misdiagnosis and mistreatment to a certain extent, and alleviate the economic burden of the country and individuals. Ye Shenglong, deputy director of Fudan University Liver Cancer Institute, said that the consensus released this time strictly follows the high-level evidence-based medical evidence obtained from clinical research in recent years. Based on these new evidences, while referring to the widely recognized guidelines in many countries and regions, etc., the consensus points out that surgery is still the preferred means of treating early-stage liver cancer; doxorubicin is listed as the standard treatment drug for advanced liver cancer. In addition, given that hepatitis B, aflatoxin, and water contamination are important high-risk factors for liver cancer, the consensus lists vaccination, water change, and mold prevention as primary prevention measures.